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Abstract: Mitochondrial fatty acid β-oxidation (FAO) is the primary pathway for fatty acid
metabolism in humans, performing a key role in liver, heart and skeletal muscle energy homeostasis.
FAO is particularly important during times of fasting when glucose supply is limited, providing
energy for many organs and tissues, including the heart, liver and brain. Deficiencies in FAO can
cause life-threatening metabolic disorders in early childhood that present with liver dysfunction,
hypoglycemia, dilated hypertrophic cardiomyopathy and Reye-like Syndrome. Alternatively,
FAO defects can also cause ‘milder’ adult-onset disease with exercise-induced myopathy and
rhabdomyolysis. Short-chain enoyl-CoA hydratase (ECHS1) is a key FAO enzyme involved
in the metabolism of fatty acyl-CoA esters. ECHS1 deficiency (ECHS1D) also causes human
disease; however, the clinical manifestation is unlike most other FAO disorders. ECHS1D patients
commonly present with Leigh syndrome, a lethal form of subacute necrotizing encephalomyelopathy
traditionally associated with defects in oxidative phosphorylation (OXPHOS). In this article, we
review the clinical, biochemical and genetic features of the ESHS1D patients described to date,
and discuss the significance of the secondary OXPHOS defects associated with ECHS1D and their
contribution to overall disease pathogenesis.
Keywords: mitochondrial disease; fatty acid oxidation; short-chain enoyl-CoA hydratase; ECHS1
deficiency; metabolism; oxidative phosphorylation; OXPHOS
1. Mitochondrial Metabolism
Mitochondria are the ‘powerhouses’ of the cell, producing 95% of all cellular energy in the
form of adenosine triphosphate (ATP) [1]. ATP is expended for essential processes such as growth,
reproduction, cell signaling and differentiation [2]. Additionally, mitochondria are involved in other
important cellular functions including apoptosis, calcium homeostasis, biosynthesis of heme and
iron-sulfur clusters, as well as innate immune responses [2,3].
Under aerobic conditions, mitochondria produce ATP via three key biochemical pathways: the
tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OXPHOS) and fatty acid β-oxidation (FAO).
Acetyl-coenzyme A (acetyl-CoA) derived from sugars, fats and proteins is oxidized via the TCA cycle
to generate the reducing equivalents nicotinamide adenine dinucleotide (NADH) and flavin adenine
dinucleotide (FADH2) [4]. NADH and FADH2 are then oxidized by complex I (NADH: ubiquinone
oxidoreductase) and complex II (succinate: ubiquinone oxidoreductase) respectively of the respiratory
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chain (RC) to drive ATP generation by OXPHOS. The electrons liberated from NADH and FADH2
are transferred via ubiquinone to complex III (ubiquinol: ferricytochrome c oxidoreductase), then
cytochrome c, and finally complex IV (cytochrome c oxidase) which reduces O2 to generate H2O. This
electron transfer facilitates the pumping of protons out of the mitochondrial matrix by complexes I, III
and IV, which establishes an electrochemical membrane potential (∆Ψm) across the inner mitochondrial
membrane (IMM) [5]. ∆Ψm drives protons back into the mitochondrial matrix through complex V
(F1F0-ATP synthase), resulting in the phosphorylation of adenosine diphosphate (ADP) to generate
ATP [5].
2. Fatty Acid β-Oxidation (FAO)
Fatty acids are the main energy source during fasting when glucose is not available, and the
preferred substrates for catabolic metabolism in the heart, liver and skeletal muscle [6]. Free fatty
acids are activated in the cytosol by acyl-CoA synthetases to form fatty acyl-CoA esters. These
are subsequently transported into the mitochondria via the carnitine shuttle system. Carnitine
O-palmitoyltransferase 1 (CPT1) catalyzes the addition of carnitine to fatty acyl-CoA esters to form
acylcarnitines, which are transported across the IMM via carnitine acylcarnitine translocase (CACT).
Once inside the mitochondrial matrix, carnitine is removed by carnitine O-palmitoyltransferase 2
(CPT2) to regenerate fatty acyl-CoA esters and free carnitine, which is recycled back across the IMM
by CACT (Figure 1).
Figure 1. Mitochondrial fatty acid β-oxidation (FAO). Enzymes of the carnitine shuttle system (yellow)
are responsible for transporting fatty acyl-CoA esters into the mitochondrial matrix as acylcarnitines.
Carnitine is added to fatty acyl-CoAs by carnitineO-palmitoyltransferase 1 (CPT1), forming acylcarnitines
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that are transported into the mitochondrial matrix by the carnitine acylcarnitine translocase (CACT).
Once inside the mitochondrial matrix, carnitine O-palmitoyltransferase 2 (CPT2) removes the carnitine
to regenerate the fatty acyl-CoA ester. Four reactions (1–4) then occur for each round of FAO, catalyzed
by enzymes with different carbon chain length specificities (as shown): 1—dehydrogenation of fatty
acyl-CoA esters by very long-chain (VLCAD), medium-chain (MCAD), and short-chain (SCAD)
acyl-CoA dehydrogenases (shown in green) to form enoyl-CoA, 2—hydration of enoyl-CoA by the
mitochondrial trifunctional protein (MTP, blue) or short-chain enoyl-CoA hydratase (ECHS1, red) to
form 3-hydroxyacyl-CoA, 3—dehydrogenation of 3-hydroxyacyl-CoA by MTP or hydroxyacyl-CoA
dehydrogenase (HADH, purple) to form 3-ketoacyl-CoA, 4—thiolysis of 3-ketoacyl-CoA by MTP or
3-ketoacyl-CoA thiolase (KAT, pink). The resulting fatty acyl-CoA is shortened by two carbons, with
the generation of acetyl-CoA, NADH and FADH2. NADH and FADH2 provide electrons for OXPHOS,
while acetyl-CoA enters the TCA cycle to generate further NADH and FADH2. The shortened fatty
acyl-CoA undergoes further rounds of FAO until only two acetyl-CoA molecules remain. MOM,
mitochondrial outer membrane; MIM, mitochondrial inner membrane.
Through a series of four enzymatic reactions, dehydrogenation, hydration, a second
dehydrogenation and thiolysis, fatty acyl-CoA chains within the mitochondria are processed to yield
one acetyl-CoA molecule, two electrons and a fatty acyl-CoA shortened by two carbons. This series of
reactions is then performed repeatedly until only two acetyl-CoA molecules remain (commonly termed
the β-oxidation spiral) (Figure 1). Both dehydrogenation steps are cofactor-dependent, resulting in the
reduction of NAD+ and FAD to NADH and FADH2, which are subsequently oxidized by OXPHOS
complexes I and II respectively [7].
The enzymes involved in FAO exhibit chain length specificity [8]. Very long-, medium-, and
short-chain acyl-CoA dehydrogenases (VLCAD, MCAD, SCAD) catalyze the first dehydrogenation
step of C24-C12, C12-C6 and C6-C4 carbon chain length fatty acyl-CoAs respectively. For the
remaining three reactions, longer acyl-CoA chains (C16-C8) are catalyzed by the multi-domain
mitochondrial trifunctional protein (MTP), which harbors long-chain enoyl-CoA hydratase, long-chain
3-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-CoA thiolase activities [9]. For medium- and
short-chain fatty acids, the last three steps of FAO are catalyzed by short-chain enoyl-CoA hydratase
(ECHS1), hydroxyacyl-CoA dehydrogenase (HADH) and 3-ketoacyl-CoA thiolase (KAT) (Figure 1).
3. ECHS1 is a Multifunctional Enzyme
Short-chain enoyl-CoA hydratase (ECHS1; EC 4.2.1.17) is responsible for the second step of FAO.
ECHS1 activity was first observed by Stern and Del Campillo [10] in ox heart and liver, with human
ECHS1 cDNA clones first isolated in 1993 [10]. The 11 kb ECHS1 gene locus was subsequently mapped
to chromosome 10q26.2–q26.3 by fluorescence in situ hybridization, encoding eight exons with the 5′
and 3′ untranslated regions contained within exons I and VIII respectively [11].
ECHS1 is transcribed as a single 1.4 kb mRNA, with expression observed in hepatocytes,
fibroblasts and myocytes [10]. The translated 290 amino acid precursor protein contains a 27-amino-acid
N-terminal mitochondrial targeting signal that is cleaved upon entry into the mitochondrial matrix [12],
where the resulting 28.3-kDa mature protein forms an active 188 kDa homohexamer composed of a
‘dimer of trimers’ [13,14] (Figure 2A).
ECHS1 catalyzes the conversion of trans-∆2-enoyl-CoA thioesters to 3-L-hydroxyacyl-CoA
thioesters by stereospecific hydration of the trans double bond between carbons two and three [15]
(Figure 2B). ECHS1 has strongest substrate affinity for the 4-carbon crotonyl-CoA, but can bind
enoyl-CoA chains up to 10 carbon atoms in length [14]. While ECHS1 has considerably higher specificity
for straight-chain enoyl-CoA thioesters as part of the FAO pathway, it also exhibits moderate activity
for degrading methacrylyl-CoA (valine pathway), 3-methylcronytyl-CoA (leucine pathway) and
tiglyl-CoA (isoleucine pathway) [16,17]. Interestingly, only metabolites of the valine pathway have
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been detected in plasma and urine of patients with ECHS1 deficiency (ECHS1D), suggesting that
ECHS1 is vital for valine metabolism, but not leucine or isoleucine metabolism [16,17].
Figure 2. ECHS1 Structure and Function. (A) Homohexameric ECHS1 crystal structure at 2.55 Å
resolution (PDB: 2hw5), showing six ECHS1 units colored by chain. Two copies of the 4-carbon
substrate crotonyl-CoA are shown (bottom right hand corner). (B) ECHS1 catalyzes the conversion of
trans-∆2-enoyl-CoA thioesters to 3-L-hydroxyacyl-CoA thioesters by stereospecific hydration of the
trans double bond between carbons two and three. Hydration of crotonyl-CoA to 3-hydroxybutyryl-
CoA is shown.
4. FAO Disease
Defects in FAO were first described in the 1970′s in patients with carnitine O-palmitoyltransferase
deficiencies [18–20], with the first pathogenic mutations identified in ACADM (which encodes the
medium-chain acyl-CoA dehydrogenase) [21–23]. Pathogenic mutations have now been identified in
at least 22 different FAO genes, and can affect up to 1 in 10,000 individuals in certain populations [1].
Patients can present in early childhood with severe (often lethal) liver dysfunction, hypoglycemia
and Reye-like syndrome (a combination of encephalopathy due to acute brain swelling and liver
dysfunction caused by fat accumulation) [24]. Cardiac symptoms, such as dilated hypertrophic
cardiomyopathy and arrhythmias, are also common [25,26]. Alternatively, ‘milder’ adult-onset disease,
presenting with exercise-induced myopathy and rhabdomyolysis (breakdown of muscle fibers), has
also been reported [27].
Disease presentation may not be persistent, with patients showing no symptoms or biochemical
deficiencies until an episode of metabolic crisis. These episodes can be triggered by various
circumstances, including prolonged fasting, exercise, infection, exposure to cold, or a fat-rich
diet [7,28,29]. Treatment options are limited, focusing on restricting dietary long-chain fatty acids that
cannot be metabolized (and which become toxic), as well as maintaining blood glucose levels.
FAO deficiencies are also believed to cause about 1–3% of unexplained sudden infant
deaths [30], with deficiencies in MCAD and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
reported [31,32]. In addition, mutations in the genes encoding MCAD, SCAD, LCHAD and CPT2 are
associated with acute fatty liver of pregnancy (AFLP) and hemolysis, elevated liver enzymes and low
platelets (HELLP) syndrome, both of which carry significant neonatal and maternal morbidity and
mortality during pregnancy [33,34].
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5. ECHS1 Deficiency (ECHS1D)
ECHS1D onset is usually at birth or in early childhood, with death occurring within the first two
days of life in some cases [35]. The clinical presentation of ECHS1D is typified by Leigh syndrome
(subacute necrotizing encephalomyelopathy) or Leigh-like syndrome, with symptoms including (but
not limited to) developmental delay, dystonia, metabolic acidosis, cardiomyopathy and apnea. Leigh
syndrome is a progressive neurodegenerative disease characterized by bilateral symmetric brain
lesions and psychomotor regression [36], and is not typically observed in other FAO disorders [37].
Leigh syndrome has been associated with more than 75 genes, mostly involved in OXPHOS complex
I structure and assembly [38]. Brain magnetic resonance imaging (MRI) findings have revealed T2
bilateral hyperintensities, a hallmark of Leigh syndrome, in almost all reported cases of ECHS1D.
Despite this, there are disparities between the clinical presentation in ECHS1D and the classical
features of Leigh syndrome (as defined in Rahman, et al. [39]). Indeed, Haack, et al. [40] proposed that
ECHS1D is a distinct form of Leigh-like syndrome associated with severe progressive encephalopathy,
accompanied by bilateral brain lesions and mitochondrial dysfunction.
More recently, three patients were identified with clinical symptoms that expand the phenotypic
spectrum of ECHS1D [41–43]. One patient harboring ECHS1 variants previously associated with
Leigh-like syndrome also presented with cutis laxa, a connective tissue disorder characterized by
loose, inelastic skin [43]. Another two patients displayed symptoms of paroxysmal exercise-induced
dyskinesia (PED) [41,42]. PED is a much milder form of ECHS1D that offers a more optimistic prognosis,
being characterized by recurrent attacks of abnormal dystonic movement that is triggered by prolonged
exercise [44]. While these PED patients were unrelated, they shared a common ECHS1 mutation
(c.518C > T; p.Ala173Val), suggesting an association between this variant and PED. Interestingly,
T2 hyperintensities were still observed in these patients, but Leigh-like symptoms were absent.
Conversely, a sibling of one of these patients did suffer from Leigh-like syndrome with severe
generalized dystonia, further exemplifying the substantial clinical heterogeneity of ECHS1D [42].
6. Pathogenic Mutations in ECHS1
Forty-two patients (from 33 families) with ECHS1D have been described to date (Table 1).
As with almost all primary disorders of FAO, ECHS1D follows an autosomal recessive pattern
of inheritance. Human mutations in ECHS1 were first described in two infant siblings [45], with
all subsequent cases exhibiting compound heterozygosity or homozygosity due to consanguinity.
Twenty-seven of the 30 different ECHS1 mutations identified are missense, suggesting that null
mutations may be incompatible with life [40,46]. Other noteworthy variants include nonsense
mutations, frameshift mutations, and duplications resulting in protein truncation [35,40,42]. The only
incidence of homozygosity for a truncating mutation was reported in two siblings with a very
severe phenotype and death within 48 h, establishing some evidence for a genotype-phenotype
relationship [35].
While most ECHS1 mutations are novel, the c.476A > G; p.Gln159Arg variant has been identified
in seven unrelated ECHS1D patients with diverse racial backgrounds [17,40,43,47,48]. Furthermore,
this variant may also represent a common founder mutation, as it has been independently reported in
two families of Pakistani origin [40,48]. A second possible founder mutation in ECHS1 (c.538A > G;
p.Thr180Ala) has also been identified in four French-Canadian patients [47]. Interestingly, this mutation
has also been identified in an Irish Traveler family with a haplotype shared with the French-Canadian
patients, suggesting an Irish ancestral origin with subsequent migration to Canada [48].
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Table 1. The clinical, biochemical and metabolic features of all reported ECHS1D patients.
Reference Peters et al. 2014 [45] Sakai et al. 2015 [49] Haack et al. 2015 [40]
Patient ID Patient 1 Patient 2 Patient 1 FI, II:2 F2: II:1 F3. II:6 F4; II:1
Age at presentation Birth 3 months 2 months Birth Birth Birth Birth
Death 4 months 8 months NL 4 months 11 months 3 years 7.5 years
Parental
consanguinity No No No No No Yes No
Mutation 1 (genetic
level; protein effect)
c.473C > A;
p.Ala158Asp
c.473C > A;
p.Ala158Asp c.2T > G; p.Met1Arg
c.176A > G;
p.Asn59Ser
c.197T > C;
p.Ile66Thr
c.476A > G;
p.Gln159Arg
c.161G > A;
p.Arg54His
Mutation 2 (genetic
level; protein effect)
c.414 + 3G > C;
splicing
c.414 + 3G > C;
splicing c.5C > T; p.Ala2Val
c.476A > G;
p.Gln159Arg
c.449A > G;
p.Asp150Gly
c.476A > G;
p.Gln159Arg
c.817A > G;
p.Lys273Glu
T2 hyperintensity Yes NL Yes Yes Yes Yes NL
Acylcarnitine profile ND ND Normal Normal Normal Normal NL
PDC activity Reduced Reduced ND ND Reduced ND ND
OXPHOS activity ND ND
Reduced CI, CIII and
CIV (patient cells),
reduced CI, CIV and
CV (immortalized
myoblasts)
Reduced CI in liver,
normal in heart
and muscle
Normal ND
Normal (but
reduced overall
ATP production)
OXPHOS complex
steady-state levels ND ND Normal ND ND ND ND
Reference Haack et al. 2015 [40] (continued)
Patient ID F5; II:3 F6, II:1 F7, II:2 F8, II:1 F9, II:2 F10, II:1
Age at presentation Birth Birth 2 years 1 year Birth 11 months
Death Alive at 2.3 years Alive at 3 years Alive at 5 years Alive at 8 years Alive at 16 years Alive at 31 years
Parental
consanguinity Yes No No No No No
Mutation 1 (genetic
level; protein effect)
c.673T > C;
p.Cys225Arg
c.98T > C;
p.Phe33Ser c.268G > A, p.Gly90Arg
c.161G > A;
p.Arg54His
c.161G > A;
p.Arg54His c.229G > C; p.Glu77Gln
Mutation 2 (genetic
level; protein effect)
c.673T > C;
p.Cys225Arg
c.176A > G;
p.Asn59Ser
c.583G > A;
p.Gly195Ser
c.394G > A;
p.Ala132Thr
c.431dup;
p.Leu145Alafs*6 c.476A > G; p.Gln159Arg
T2 hyperintensity Yes Yes Yes ND Yes Yes
Acylcarnitine profile Normal Normal NL NL NL NL
PDC activity ND ND ND ND Normal ND
OXPHOS activity Normal Reduced CIVin muscle Normal ND Normal Normal
OXPHOS complex
steady-state levels ND ND ND ND ND ND
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Table 1. Cont.
Reference Ferdinandusse et al. 2015 [17] Tetreault et al. 2015 [47]
Patient ID Patient 1 Patient 2 Patient 3 Patient 4 P1 P2 P3 P4
Age at presentation Birth Birth Early infancy 1 year 2.5 months 2.9 years 10 months 6 months
Death 24 h 2 days Alive at 7 years 3 years 10 months Alive at 18 years Alive at 13 years Alive at 12 years
Parental
consanguinity Yes Yes No No No No No No
Mutation 1 (genetic
level; protein effect)
c.817A > G;
p.Lys273Glu
c.817 > G;
p.Lys273Glu
c.433C > T;
p.Leu145Phe
c.673T > C;
p.Cys225Arg
c.538A > G;
p.Thr180Ala
c.538A > G;
p.Thr180Ala
c.538A > G;
p.Thr180Ala
c.538A > G;
p.Thr180Ala
Mutation 2 (genetic
level; protein effect)
c.817A > G;
p.Lys273Glu
c.817A > G;
p.Lys273Glu
c.476A > G;
p.Gln159Arg
c.674G > C;
p.Cys225Ser
c.583G > A;
p.Gly195Ser
c.713C > T;
p.Ala238Val
c.713C > T;
p.Ala238Val
c.476A > G;
p.Gln159Arg
T2 hyperintensity ND Yes NL Yes Yes Yes Yes Yes
Acylcarnitine profile Normal Normal Normal Normal Normal Normal Normal Normal
PDC activity Reduced Reduced ND ND Reduced Normal ND Normal
OXPHOS activity Normal Normal ND ND
Mild reduction of
CI and CIII
in muscle
Normal Normal Normal
OXPHOS complex
steady-state levels Normal Normal ND ND ND ND ND
Reduced CIV in
fibroblasts
Reference Yamada et al. 2015 [16] Ganetzky et al. 2016 [50] Olgiati et al. 2016 [42] Nair et al. 2016 [46]
Patient ID III-2 III-3 Patient 1 Patient 2 II-1 II-2 Patient 1
Age at presentation 10 months 7 months Prenatal Prenatal 3.5 years 4.5 years Birth
Death Alive at 7 years 5 years 16 h 24 h Alive at 17 years Alive at 15 years 24 h
Parental
consanguinity No No No No No No Yes
Mutation 1 (genetic
level; protein effect)
c.176A > G;
p.Asn59Ser
c.176A > G;
p.Asn59Ser
c.8C > A;
p.Ala3Asp
c.8C > A;
p.Ala3Asp
c.232G > T;
p.Glu78Ter
c.232G > T;
p.Glu78Ter c.842A > G; p.Glu281Gly
Mutation 2 (genetic
level; protein effect)
c.413C > T;
p.Ala138Val
c.413C > T;
p.Ala138Val
c.389T > A;
p.Val130Asp
c.389T > A;
p.Val130Asp
c.518C > T;
p.Ala173Val
c.518C > T;
p.Ala173Val c.842A > G; p.Glu281Gly
T2 hyperintensity Yes Yes ND ND Yes Yes ND
Acylcarnitine profile Normal Normal Mild C4elevation
Mild C4
elevation ND ND Elevated C4 and C6
PDC activity ND ND ND ND ND ND ND
OXPHOS activity Normal ND ND ND ND ND ND
OXPHOS complex
steady-state levels ND ND ND ND ND ND ND
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Table 1. Cont.
Reference Mahajan et al.2017 [41] Al Mutairi et al. 2017 [35]
Balasubramaniam et al. 2017
[43] Bedoyan et al. 2017 [51]
Huffnagel et al.
2017 [52]
Patient ID Patient 1 Patient 1 Patient 2 Patient 1 Patient 1 Patient 1
Age at presentation 8 years Birth Birth 17 months Birth 6 weeks
Death Alive at 8 years 2 days 8 ho Alive at 4.5 years 39 days Alive at 26 years
Parental
consanguinity No Yes Yes No No No
Mutation 1 (genetic
level; protein effect)
c.518C > T;
p.Ala173Val
c.88 + 5G > A;
p.Ala31Glufs*23
c.88 + 5G > A;
p.Ala31Glufs*23 c.476A > G; p.Gln159Arg c.836T > C; p.Phe279Ser
c.229G > C
p.Glu77Gln
Mutation 2 (genetic
level; protein effect)
c.817A > G;
p.Lys273Glu
c.88 + 5G > A;
p.Ala31Glufs*23
c.88 + 5G > A;
p.Ala31Glufs*23 c.538A > G; p.Thr180Ala c.8C > A; p.Ala3Asp
c.563C > T
p.Ala188Val
T2 hyperintensity Yes ND ND Yes Yes Yes
Acylcarnitine profile ND Mild C3, C4, C5 andC10 elevation Normal ND ND Normal
PDC activity ND Reduced Normal ND Reduced ND
OXPHOS activity ND ND Normal ND Reduced Normal
OXPHOS complex
steady-state levels ND ND ND ND ND ND
Reference Ogawa et al. 2017 [53] Fitzsimons et al. 2018 [48]
Patient ID Pt376 Pt536 Pt1038 Pt1135 Patient 1 Patient 2 Patient 3 Patient 4
Age at presentation NL NL NL NL 5 months 3 months 5 months 2 weeks
Death NL NL NL NL 3 years 21 months 28 months 13 months
Parental
consanguinity No No No No Yes Yes Yes Yes
Mutation 1 (genetic
level; protein effect)
c.98T > C;
p.Phe33Ser c.5C > T; p.Ala2Val c.5C > T; p.Ala2Val
c.5C > T;
p.Ala2Val
c.476A > G;
p.Gln159Arg
c.538A > G;
p.Thr180Ala c.538A > G; p.Thr180Ala
c.538A > G;
p.Thr180Ala
Mutation 2 (genetic
level; protein effect)
c.176A > G;
p.Asn59Ser c.1A > G; p.Met1Val c.176A > G; p.Asn59Ser
c.176A > G;
p.Asn59Ser
c.476A > G;
p.Gln159Arg
c.538A > G;
p.Thr180Ala c.538A > G; p.Thr180Ala
c.538A > G;
p.Thr180Ala
T2 hyperintensity ND ND ND ND Yes Yes Yes Yes
Acylcarnitine profile ND ND ND ND Normal ND
Mild reduction of free
carnitine and long-chain
acylcarnitines
Normal
PDC activity ND ND ND ND Reduced ND Normal ND
OXPHOS activity Reduced CIV Normal Normal (but reducedoxygen consumption rate)
Reduced
CI Normal ND Reduced CIII in muscle ND
OXPHOS complex
steady-state levels ND ND ND ND ND ND ND ND
T2 hyperintensity refers to regions of high intensity on T2 weighted magnetic resonance imaging scans of the brain. OXPHOS complex steady-state levels were determined by blue native
polyacrylamide gel electrophoresis. PDC, pyruvate dehydrogenase complex; OXPHOS, oxidative phosphorylation; ND, not determined; NL, not listed; CI, complex I; CIII, complex III;
CIV, complex IV; CV, complex V; C3DC, malonylcarnitine; C4, butyrylcarnitine; C5DC, glutarylcarnitine; C6, hexanoylcarnitine; C10, decanoylcarnitine.
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7. Biochemical and Metabolic Characterization of ECHS1D
ECHS1 may play a redundant role in FAO, as exemplified by the unremarkable acylcarnitine
profiles in most patient cells [16,17,35,40,47–50,52]. However, extremely high acylcarnitine levels (of C6
and C4 chain lengths) were reported in one patient who died within one day of birth [46]. As such,
elevated acylcarnitines may act as an indicator of disease in only the most severe cases of ECHS1D.
Loss of ECHS1 activity for valine metabolism also appears to play a role in disease pathology.
ECHS1 acts on both methacrylyl-CoA from the valine pathway and acryloyl-CoA from an alternate
pathway of odd-chain FAO that feeds into the valine pathway [54]. In ECHS1D, these two
intermediates accumulate, becoming toxic by spontaneous reaction with thiol groups and other
mitochondrial cysteine residues, resulting in impaired ATP production and metabolic acidosis [55].
Specifically, methacrylyl-CoA and acryloyl-CoA react with lipoyl domains of the E2 subunit of the
pyruvate dehydrogenase complex (PDC), inhibiting its function [17]. Indeed, reduced PDC activity
has been observed in many ECHS1D patients, explaining the commonly observed symptom of
lactic acidosis [17,35,40,43,45,47,48,51,52]. Notably, an inhibitory effect on two other lipoyl domain-
containing mitochondrial enzymes was not detected [17], suggesting inhibition is specific to the PDC
(via an unknown mechanism).
These findings have led to tentative correlations between ECHS1D severity, degree of lactic
acidosis and reduced PDC activity. In cases where ECHS1D caused early death, lactate levels were high
and PDC activity low [35]. Conversely, in mild cases of ECHS1D, lactic acidosis was absent [16,41,42].
Other metabolic markers of ECHS1D, such as increased metabolites of methacrylyl-CoA
and acryloyl-CoA in patient urine, have also been identified [45]. In particular, large peaks of
2-methyl-2,3-dihydroxybutyrate have been detected in many ECHS1D cases [40,45,48,50,51]. While
the origin of 2-methyl-2,3-dihydroxybutyrate is not known, evidence suggests it is a derivative of
acryloyl-CoA [45]. Despite these findings, 2-methyl-2,3-dihydroxybutyrate concentrations have
repeatedly measured within the normal range in milder ECHS1D cases [16,17,40,42]. Conversely,
N-acetyl-S-(2-carboxypropyl)cysteine (produced from methacrylyl-CoA) is the only known metabolite
that is elevated in the mildest cases of ECHS1D, making it the most useful biomarker for ECHS1D
diagnosis [16,42,52].
8. Secondary OXPHOS Defects in ECHS1D
FAO and OXPHOS are tightly linked biochemically, with the oxidation of fatty acids generating
NADH and FADH2 for oxidation by OXPHOS complexes I and II. In addition, studies have also
reported physical interactions between FAO and OXPHOS proteins: OXPHOS complex I can bind
the FAO protein LCHAD [56], while OXPHOS complex III can be purified in complexes with the
FAO electron transfer flavoprotein (ETF) [57]. More recently, the FAO proteins VLCAD, MCAD,
LCHAD, and ETF were shown to co-migrate with the OXPHOS supercomplex in a metabolically active
super-structure that can oxidize fatty acids [58].
Interestingly, patients with primary deficiencies in LCHAD can exhibit significant OXPHOS
enzyme defects [26,59]. These secondary OXPHOS defects were historically attributed to the
accumulation of inhibitory fatty-acyl CoA intermediates. However, it now appears that more complex
mechanisms are involved. Indeed, we recently showed that loss of the FAO protein MCAD can disrupt
OXPHOS complex assembly and stability, resulting in reduced mitochondrial respiration and increased
ROS generation in the presence of OXPHOS inhibitors [60].
Secondary OXPHOS defects have also been identified in ECHS1D. These range from isolated
defects in complex I, complex III or complex IV to multiple complex I/III/IV or complex I/IV/V
defects [40,47–49,53]. Furthermore, blue native polyacrylamide gel electrophoresis (BN-PAGE) has
identified reduced steady-state levels of mature complex IV in one patient [47]. Conversely, no
differences in complex IV levels were detected in three other ECHS1D patients [17,49].
While it is not clear what causes these secondary OXPHOS defects in ECHS1D, disruption of
complex I activity may be explained via its interaction with the pyruvate dehydrogenase complex
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(PDC). As discussed above, toxic metabolites of the valine pathway can accumulate in ECHS1D and
inhibit PDC activity [17]. This inhibition may disrupt the binding of complex I to the PDC [56], with a
potential loss of both complex I stability and NADH dehydrogenase activity.
Overall, it is difficult to predict the effect of ECHS1D on OXPHOS. However, it is apparent that
patients with secondary OXPHOS defects generally exhibit more severe Leigh-like symptoms (Table 1).
9. Concluding Remarks
Forty patients have been described with pathogenic mutations in ECHS1 since the identification
of the first two patients with ECHS1D in 2014. Notably, most ECHS1D patients present with Leigh
syndrome or Leigh-like syndrome, a severe disorder traditionally associated with defects in OXPHOS
complex I activity. While loss of ECHS1 disrupts both FAO and valine metabolism, secondary OXPHOS
defects have also been identified in some patients with ECHS1D. Furthermore, these secondary
OXPHOS defects are associated with a more severe clinical phenotype, suggesting that they also
contribute to disease pathology.
Like other FAO deficiencies, secondary OXPHOS defects in ECHS1D may be due to the
accumulation of toxic fatty acid and/or valine metabolites, which can directly inhibit OXPHOS
complex activity. Alternatively, the effects of these metabolites may be indirect by disrupting the
interaction between the pyruvate dehydrogenase complex (PDC) and OXPHOS complex I. Whichever
mechanism is involved, further research is required to clarify the relationship between ECHS1D and
OXPHOS dysfunction, and to determine if the stability and/or biogenesis of the OXPHOS complexes
is also disrupted by the loss of ECHS1. This knowledge will be invaluable for our understanding
of the complex interactions between the FAO and OXPHOS pathways, and will help to advance the
diagnosis and treatment of mitochondrial disorders such as ECHS1D.
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